Edition:
United States

Coherus BioSciences Inc (CHRS.OQ)

CHRS.OQ on NASDAQ Stock Exchange Global Market

8.60USD
3:59pm EST
Change (% chg)

$0.00 (+0.00%)
Prev Close
$8.60
Open
$8.55
Day's High
$8.90
Day's Low
$8.45
Volume
96,337
Avg. Vol
137,668
52-wk High
$29.35
52-wk Low
$8.07

Latest Key Developments (Source: Significant Developments)

Coherus Says Judge Issued Under Seal Report & Recommendation In Relation To Patent Infringement Complaint
Friday, 8 Dec 2017 01:11pm EST 

Dec 8 (Reuters) - Coherus Biosciences :COHERUS SAYS U.S. JUDGE RECOMMENDED COURT GRANT CO'S PENDING MOTION TO DISMISS AMGEN'S COMPLAINT FOR FAILURE TO STATE CLAIM .COHERUS BIOSCIENCES SAYS ON DEC 7, JUDGE ISSUED UNDER SEAL REPORT AND RECOMMENDATION TO DISTRICT COURT IN RELATION TO PATENT INFRINGEMENT COMPLAINT.COHERUS BIOSCIENCES SAYS CO EXPECTS DISTRICT COURT TO DECIDE IN Q1 2018 WHETHER TO ADOPT MAGISTRATE JUDGE'S RECOMMENDATION - SEC FILING.COHERUS BIOSCIENCES SAYS ‍REPORT AND RECOMMENDATION ISSUED BY JUDGE WITH RESPECT TO LITIGATION BETWEEN AMGEN, AMGEN MANUFACTURING LTD, CO​.  Full Article

Coherus Biosciences Q3 loss per share $1.09
Monday, 6 Nov 2017 04:00pm EST 

Nov 6 (Reuters) - Coherus Biosciences Inc :Coherus Biosciences reports third quarter 2017 operating and financial results.Q3 loss per share $1.09.Q3 earnings per share view $-0.81 -- Thomson Reuters I/B/E/S.Coherus biosciences inc - ‍anticipate cash use in operations of about $35 - $40 million in Q4 of 2017​.  Full Article

Coherus Biosciences files for offering of upto 6.56 million shares of common stock by the selling stockholder‍​
Friday, 22 Sep 2017 05:35pm EDT 

Sept 22 (Reuters) - Coherus Biosciences Inc :Coherus Biosciences Inc - Files for offering of upto 6.56 million shares of common stock by the selling stockholder‍​ - SEC filing.  Full Article

Coherus Biosciences says ‍PTAB denied 4 petitions for inter partes review of Abbvie's patent
Thursday, 7 Sep 2017 11:57am EDT 

Sept 7 (Reuters) - Coherus Biosciences Inc :Coherus Biosciences provides update on ‘619 IPR institution decision.Says ‍PTAB denied institution of all 4 petitions for inter partes review of Abbvie's patent related to Abbvie's Humira formulation​.  Full Article

Coherus Biosciences announces positive topline results for study for Humira biosimilar vs European marketed Humira in healthy subjects
Monday, 28 Aug 2017 08:30am EDT 

Aug 28 (Reuters) - Coherus Biosciences Inc :Coherus Biosciences announces positive topline results for clinical pharmacokinetic bioequivalence study for CHS-1420 (Humira® biosimilar candidate) versus European marketed Humira in healthy subjects.Coherus Biosciences Inc - ‍Study met criteria for clinical PK/BE on all prospectively defined endpoints​.Coherus Biosciences - ‍Both agents well tolerated, there were no clinical meaningful differential adverse events observed between two agents in study​.  Full Article

Coherus secures private placement from Temasek
Monday, 21 Aug 2017 08:30am EDT 

Aug 21 (Reuters) - Coherus Biosciences Inc :Coherus secures private placement from Temasek.Coherus Biosciences Inc - ‍Temasek plans to invest up to $150 million over two tranches​.Coherus Biosciences Inc - ‍First tranche of $75 million in gross proceeds to be completed and funded by August 31, 2017 with 6.6 million shares of common stock​.Coherus Biosciences Inc - ‍Second tranche is projected to be funded following receipt of U.S. FDA marketing approval for CHS-1701​.Coherus Biosciences - Intends to use net proceeds from private placements for capital for completion of development and registration of CHS-1701.  Full Article

Coherus Biosciences Q2 loss $1.08 per share
Monday, 7 Aug 2017 04:00pm EDT 

Aug 7 (Reuters) - Coherus Biosciences Inc ::Anticipate resubmitting BLA in U.S. At end of Q4 of 2017 for CHS-1701 .Coherus Biosciences reports second quarter 2017 corporate highlights and financial results.Q2 revenue $1.4 million versus $14.1 million.Q2 revenue view $5.2 million -- Thomson Reuters I/B/E/S.Q2 loss per share $1.08.Q2 earnings per share view $-1.20 -- Thomson Reuters I/B/E/S.Anticipates cash usage of about $40 - $45 million per quarter in h2 2017 and $30 - $35 million per quarter in first half of 2018.  Full Article

Coherus Biosciences says completed restructuring plan to reduce operating costs
Tuesday, 27 Jun 2017 04:08pm EDT 

June 27 (Reuters) - Coherus Biosciences Inc :Says commenced and completed, a restructuring plan to reduce operating costs and better align its workforce.Coherus biosciences - decision followed u.s. Fda's june 12, issuance of complete response letter for chs-1701.Says under this plan, company reduced its workforce by 51 employees (approximately 30%).Coherus biosciences says it estimates that it will incur aggregate restructuring charges of about $3.7 million, which will be recorded in q2 of 2017.Coherus biosciences - majority of cash payments related to personnel-related restructuring charges will be paid during q3 of 2017.Says expects that workforce reduction will decrease its annual operating costs by approximately $10 million.  Full Article

Coherus to take nearly 6 months to respond to FDA's requests on Neulasta biosmilar
Monday, 12 Jun 2017 09:30am EDT 

June 12 (Reuters) - Coherus BioSciences Inc -:Coherus BioSciences Inc says the agency can take up to 6 months to evaluate the requested information.Coherus Biosciences Inc says it will generate responses to the complete response letter within 6 months: conf call.  Full Article

Coherus Biosciences receives CRL from FDA for biologics license application for CHS-1701
Monday, 12 Jun 2017 06:38am EDT 

June 12 (Reuters) - Coherus Biosciences Inc :Coherus Biosciences receives complete response letter from fda for its biologics license application for chs-1701 (pegfilgrastim biosimilar candidate).Coherus will work with fda to address information requests.Coherus Biosciences -crl primarily focused on fda request for a reanalysis of a subset of subject samples with a revised immunogenicity assay.Coherus Biosciences inc - fda did not request a clinical study to be performed in oncology patients.Coherus Biosciences inc says crl also focused on fda requests for certain additional manufacturing related process information.Coherus Biosciences-‍crl does not indicate additional process qualification lots would be required or raise concerns on gmp status of chs-1701 bulk manufacturing.  Full Article

BRIEF-Coherus Says Judge Issued Under Seal Report & Recommendation In Relation To Patent Infringement Complaint

* COHERUS SAYS U.S. JUDGE RECOMMENDED COURT GRANT CO'S PENDING MOTION TO DISMISS AMGEN'S COMPLAINT FOR FAILURE TO STATE CLAIM